Sweeney & Michel LLC Invests $1.33 Million in AbbVie Inc. (NYSE:ABBV)

Sweeney & Michel LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBVFree Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,851 shares of the company’s stock, valued at approximately $1,334,000. AbbVie accounts for 0.7% of Sweeney & Michel LLC’s holdings, making the stock its 24th biggest position.

Several other hedge funds have also added to or reduced their stakes in the stock. Kalos Management Inc. bought a new stake in AbbVie in the 1st quarter valued at about $26,000. Boulder Wealth Advisors LLC bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC bought a new stake in shares of AbbVie in the first quarter valued at approximately $37,000. True Wealth Design LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at approximately $39,000. Finally, General Partner Inc. bought a new position in AbbVie in the 1st quarter worth approximately $40,000. Institutional investors own 67.86% of the company’s stock.

AbbVie Price Performance

ABBV opened at $151.19 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.77 and a debt-to-equity ratio of 4.33. The stock has a market capitalization of $266.86 billion, a P/E ratio of 31.11, a PEG ratio of 2.70 and a beta of 0.58. The stock has a 50-day moving average price of $145.76 and a 200-day moving average price of $147.52. AbbVie Inc. has a 12-month low of $130.96 and a 12-month high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last issued its quarterly earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.79 by $0.12. The business had revenue of $13.87 billion for the quarter, compared to analysts’ expectations of $13.52 billion. AbbVie had a net margin of 15.50% and a return on equity of 151.29%. Equities analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a dividend of $1.48 per share. The ex-dividend date is Thursday, October 12th. This represents a $5.92 annualized dividend and a yield of 3.92%. AbbVie’s payout ratio is 121.81%.

Analysts Set New Price Targets

Several research firms have issued reports on ABBV. Piper Sandler increased their target price on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. HSBC assumed coverage on AbbVie in a report on Friday, July 14th. They set a “buy” rating and a $167.00 price objective on the stock. Piper Jaffray Companies lifted their target price on AbbVie from $163.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, July 28th. Credit Suisse Group lowered their price target on shares of AbbVie from $170.00 to $160.00 in a report on Wednesday, July 12th. Finally, StockNews.com initiated coverage on shares of AbbVie in a research note on Thursday, August 17th. They set a “strong-buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $165.79.

Check Out Our Latest Research Report on ABBV

Insider Activity

In other news, CEO Richard A. Gonzalez sold 18,500 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the completion of the sale, the chief executive officer now owns 625,294 shares of the company’s stock, valued at $93,262,600.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

See Also

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.